Jay Bradner, NIBR president

In pur­suit of ac­ces­si­ble sick­le cell cure, No­var­tis inks $1.5B deal to tap Pre­ci­sion's AR­CUS gene edit­ing tech

No­var­tis brought in an­oth­er biotech part­ner on its quest to cre­ate an in vi­vo gene edit­ing ther­a­py for sick­le cell dis­ease and oth­er sim­i­lar blood dis­or­ders.

Tap­ping Pre­ci­sion Bio­Sciences’ AR­CUS genome edit­ing plat­form, No­var­tis will hand over $75 mil­lion up­front to de­vel­op a cus­tom AR­CUS nu­cle­ase that can be used to in­sert a tar­get trans­gene at a spe­cif­ic lo­ca­tion in the genome. Ac­cord­ing to the com­pa­nies, it could be­come an op­tion for a num­ber of he­mo­glo­binopathies such as be­ta tha­lassemia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.